back forth starboard
bottom line new extens slide present emerg bristol
starboard make case bristol propos
acquisit celgen respect make compel argument
key point disagr valu assign
celgen pipelin starboard believ bristol pay
pipelin almost much bristol indic bristol
hand estim celgen pipelin worth deriv
consensu forecast time median transact
multipl bristol calcul ultim pay base
assess valu celgen base busi deal synergi
continu believ key deal recommend
proxi advisori firm expect next week
price month
 close
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
bristol-my squibb compani bm engag discoveri
develop licens manufactur market distribut
sale pharmaceut product global basi
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base greater sale
opdivo/i-o eliqui yervoy compar current base case
assumpt blue sky valuat base dcf driven
wacc termin valu
grey sky valuat base lower sale opdivo/i-
eliqui yervoy compar current base case assumpt
grey sky valuat base dcf driven wacc
 close
starboard advoc stand-alon oper effici main argument
starboard present larg present previous slide
provid greater support detail starboard posit see potenti valu
eros result larg deal one view bristol assumpt
regard valu could gener pipelin aggress starboard
also maintain bristol rational deal may defens believ
greater potenti valu creation oper effici note
bristol ceo state engag high-level discuss
compani sinc highlight bristol product mix notabl eliqui
share prevent easi comparison bristol margin
peer also see rational bristol invest aggress
 time given opportun remain immuno-oncolog addit
investor spoken see less merit starboard view strength
bristol stand-alon given starboard take materi stake bristol
celgen deal announc
bristol see potenti signific pipelin valu creation bristol updat
present also contain inform larg provid previous also
provid support extent due dilig process show
compar larg deal creat valu long term present view
acquir pipelin compar celgen propos price unachiev via
larg deal biopharma face potenti challeng integr two larg
compani may also long-term benefit larger entiti abl
compet aggress stand-alon entiti
compani mention price
